QIAGEN Expands QIAcuity Digital PCR Ecosystem with New Assays and Automation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Expansion of Gene Expression Solutions: QIAGEN plans to launch new QIAcuity Gene Expression Assays in 2026, designed to support gene expression analysis across human, mouse, and rat applications, which is expected to significantly enhance research capabilities and market demand in the biopharma sector.
- Enhanced Quality Control for Cell and Gene Therapy: The company is expanding its residual DNA testing portfolio to support additional producer cell systems, thereby improving quality control in biopharmaceutical development and manufacturing workflows, which strengthens its competitive position in the market.
- Improved Automated Analysis and Reporting: The upcoming release of QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities, helping laboratories standardize data interpretation and improve efficiency, particularly in larger-scale and regulated workflows.
- Integration of Laboratory Automation: Through collaboration with Hamilton, QIAGEN has automated the setup and handling of QIAcuity dPCR nanoplate workflows, further increasing productivity in high-throughput laboratories while minimizing risks associated with manual handling.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QGEN
Wall Street analysts forecast QGEN stock price to rise
14 Analyst Rating
8 Buy
6 Hold
0 Sell
Moderate Buy
Current: 37.420
Low
45.00
Averages
50.57
High
55.00
Current: 37.420
Low
45.00
Averages
50.57
High
55.00
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QIAGEN Expands QIAcuity Digital PCR Ecosystem with New Assays and Automation
- Expansion of Gene Expression Solutions: QIAGEN plans to launch new QIAcuity Gene Expression Assays in 2026, designed to support gene expression analysis across human, mouse, and rat applications, which is expected to significantly enhance research capabilities and market demand in the biopharma sector.
- Enhanced Quality Control for Cell and Gene Therapy: The company is expanding its residual DNA testing portfolio to support additional producer cell systems, thereby improving quality control in biopharmaceutical development and manufacturing workflows, which strengthens its competitive position in the market.
- Improved Automated Analysis and Reporting: The upcoming release of QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities, helping laboratories standardize data interpretation and improve efficiency, particularly in larger-scale and regulated workflows.
- Integration of Laboratory Automation: Through collaboration with Hamilton, QIAGEN has automated the setup and handling of QIAcuity dPCR nanoplate workflows, further increasing productivity in high-throughput laboratories while minimizing risks associated with manual handling.
See More
Pomerantz LLP Investigates Qiagen for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims against Qiagen N.V. regarding potential securities fraud, focusing on whether the company and its executives engaged in unlawful business practices that could harm investors.
- Sales Decline: In its preliminary results for Q1 2026, Qiagen reported a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales dropping about 5%, indicating weak market demand.
- Stock Price Reaction: Following the sales decline announcement, Qiagen's stock price fell by $4.07, or 10.69%, closing at $34.02 per share on April 28, 2026, reflecting investor concerns about the company's outlook.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud, which could significantly impact Qiagen's legal liabilities.
See More
Pomerantz LLP Investigates Qiagen for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Qiagen N.V. regarding potential securities fraud, focusing on whether the company and its executives engaged in unlawful business practices that could harm investors.
- Sales Performance Decline: In its preliminary results for Q1 2026, Qiagen reported a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales dropping about 5%, indicating weak market demand.
- Significant Stock Price Drop: Following the earnings announcement, Qiagen's stock price fell by $4.07, or 10.69%, closing at $34.02 per share on April 28, 2026, reflecting investor concerns about the company's outlook.
- Potential Legal Action: Given the sales decline and stock price drop, investors may face the risk of a class action lawsuit, with Pomerantz LLP offering legal support to seek compensation for affected investors.
See More
Qiagen Under Investigation for Securities Fraud Claims
- Sales Performance Decline: Qiagen's preliminary results for Q1 2026 revealed a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales down about 5%, indicating pressure in market competition that could hinder future revenue growth.
- Significant Stock Drop: Following the disappointing performance, Qiagen's stock price fell by $4.07, or 10.69%, closing at $34.02 per share on April 28, 2026, which may lead to decreased investor confidence and further impact the company's market capitalization.
- Legal Investigation Initiated: Pomerantz LLP is investigating Qiagen and its executives for potential securities fraud or other unlawful business practices, which could expose the company to legal liabilities and potential damages, increasing risks for investors.
- Investor Contact Information: Pomerantz LLP is encouraging affected investors to reach out via provided email and phone details to join the class action, highlighting the potential for legal action and its implications for the company's reputation.
See More
Qiagen Under Investigation for Possible Securities Law Violations
- Sales Decline: Qiagen's preliminary results for Q1 2026 indicate a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales down about 5%, reflecting competitive pressures that could hinder future revenue growth.
- Stock Price Drop: Following the earnings announcement on April 27, 2026, Qiagen's stock price fell from $38.09 to $34.02 per share, a decline of about 11%, signaling increasing investor concerns regarding the company's performance and potentially eroding investor confidence.
- Legal Investigation: Kirby McInerney LLP is investigating possible violations of federal securities laws by Qiagen and its senior management; while no lawsuit has been filed yet, this inquiry could significantly impact the company's reputation and future legal liabilities.
- Investor Attention: The investigation has drawn the attention of investors interested in Qiagen securities, potentially leading to more shareholders seeking legal advice to protect their interests, which could further affect the company's market performance and shareholder trust.
See More
Bragar Eagel & Squire Investigates Potential Claims Against Qiagen
- Legal Investigation Launched: Bragar Eagel & Squire is investigating whether Qiagen has violated federal securities laws, which could impact investor confidence and the company's reputation.
- Declining Financial Performance: Qiagen's Q1 2026 report indicated a 1% decline in net sales on a constant exchange rate basis, with QuantiFERON product sales down approximately 5%, raising concerns about future performance among investors.
- Stock Price Volatility: Following the financial report on April 27, 2026, Qiagen's stock price fell from $38.09 to $34.02, a drop of about 11%, reflecting negative market sentiment regarding the company's financial health.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to reach out to discuss legal options, demonstrating the firm's commitment to safeguarding shareholder rights and potentially leading to further legal actions.
See More
QIAGEN Expands QIAcuity Digital PCR Ecosystem with New Assays and Automation
- Expansion of Gene Expression Solutions: QIAGEN plans to launch new QIAcuity Gene Expression Assays in 2026, designed to support gene expression analysis across human, mouse, and rat applications, which is expected to significantly enhance research capabilities and market demand in the biopharma sector.
- Enhanced Quality Control for Cell and Gene Therapy: The company is expanding its residual DNA testing portfolio to support additional producer cell systems, thereby improving quality control in biopharmaceutical development and manufacturing workflows, which strengthens its competitive position in the market.
- Improved Automated Analysis and Reporting: The upcoming release of QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities, helping laboratories standardize data interpretation and improve efficiency, particularly in larger-scale and regulated workflows.
- Integration of Laboratory Automation: Through collaboration with Hamilton, QIAGEN has automated the setup and handling of QIAcuity dPCR nanoplate workflows, further increasing productivity in high-throughput laboratories while minimizing risks associated with manual handling.
See More
Pomerantz LLP Investigates Qiagen for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims against Qiagen N.V. regarding potential securities fraud, focusing on whether the company and its executives engaged in unlawful business practices that could harm investors.
- Sales Decline: In its preliminary results for Q1 2026, Qiagen reported a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales dropping about 5%, indicating weak market demand.
- Stock Price Reaction: Following the sales decline announcement, Qiagen's stock price fell by $4.07, or 10.69%, closing at $34.02 per share on April 28, 2026, reflecting investor concerns about the company's outlook.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud, which could significantly impact Qiagen's legal liabilities.
See More
Pomerantz LLP Investigates Qiagen for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Qiagen N.V. regarding potential securities fraud, focusing on whether the company and its executives engaged in unlawful business practices that could harm investors.
- Sales Performance Decline: In its preliminary results for Q1 2026, Qiagen reported a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales dropping about 5%, indicating weak market demand.
- Significant Stock Price Drop: Following the earnings announcement, Qiagen's stock price fell by $4.07, or 10.69%, closing at $34.02 per share on April 28, 2026, reflecting investor concerns about the company's outlook.
- Potential Legal Action: Given the sales decline and stock price drop, investors may face the risk of a class action lawsuit, with Pomerantz LLP offering legal support to seek compensation for affected investors.
See More
Qiagen Under Investigation for Securities Fraud Claims
- Sales Performance Decline: Qiagen's preliminary results for Q1 2026 revealed a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales down about 5%, indicating pressure in market competition that could hinder future revenue growth.
- Significant Stock Drop: Following the disappointing performance, Qiagen's stock price fell by $4.07, or 10.69%, closing at $34.02 per share on April 28, 2026, which may lead to decreased investor confidence and further impact the company's market capitalization.
- Legal Investigation Initiated: Pomerantz LLP is investigating Qiagen and its executives for potential securities fraud or other unlawful business practices, which could expose the company to legal liabilities and potential damages, increasing risks for investors.
- Investor Contact Information: Pomerantz LLP is encouraging affected investors to reach out via provided email and phone details to join the class action, highlighting the potential for legal action and its implications for the company's reputation.
See More
Qiagen Under Investigation for Possible Securities Law Violations
- Sales Decline: Qiagen's preliminary results for Q1 2026 indicate a net sales decline of approximately 1% on a constant exchange rate basis, with QuantiFERON product sales down about 5%, reflecting competitive pressures that could hinder future revenue growth.
- Stock Price Drop: Following the earnings announcement on April 27, 2026, Qiagen's stock price fell from $38.09 to $34.02 per share, a decline of about 11%, signaling increasing investor concerns regarding the company's performance and potentially eroding investor confidence.
- Legal Investigation: Kirby McInerney LLP is investigating possible violations of federal securities laws by Qiagen and its senior management; while no lawsuit has been filed yet, this inquiry could significantly impact the company's reputation and future legal liabilities.
- Investor Attention: The investigation has drawn the attention of investors interested in Qiagen securities, potentially leading to more shareholders seeking legal advice to protect their interests, which could further affect the company's market performance and shareholder trust.
See More
Bragar Eagel & Squire Investigates Potential Claims Against Qiagen
- Legal Investigation Launched: Bragar Eagel & Squire is investigating whether Qiagen has violated federal securities laws, which could impact investor confidence and the company's reputation.
- Declining Financial Performance: Qiagen's Q1 2026 report indicated a 1% decline in net sales on a constant exchange rate basis, with QuantiFERON product sales down approximately 5%, raising concerns about future performance among investors.
- Stock Price Volatility: Following the financial report on April 27, 2026, Qiagen's stock price fell from $38.09 to $34.02, a drop of about 11%, reflecting negative market sentiment regarding the company's financial health.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to reach out to discuss legal options, demonstrating the firm's commitment to safeguarding shareholder rights and potentially leading to further legal actions.
See More
